发作性睡病药物市场规模、份额、成长分析，按疾病类型、治疗药物类型、地区划分 - 产业预测，2024-2031 年

Narcolepsy Drugs Market Size, Share, Growth Analysis, By Disease Type (Daytime Extreme Sleepiness, Cataplexia), By Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球发作性睡病药物市场规模估值约34亿美元，高于2023年的37亿美元，预测期内（2024-2031年）复合年增长率为9.5%，预计将达10亿美元。

由于几个关键因素，包括人口老化，更容易患需要医疗照护的慢性和急性疾病，预计发作性睡病药物市场将显着增长。生活方式的改变和压力水平的上升加剧了发作性睡病的增加，预计未来几年将进一步推动市场扩张。加强研究倡议、增加医疗支出和改善医疗基础设施支持了这一成长潜力。此外，我们的研究结果表明，调整昼夜节律、增加睡眠时间和实施远程办公等因素可以有效控制与中枢性嗜睡症相关的症状，从而鼓励人们广泛接受发作性睡病治疗。然而，治疗和诊断相关的高成本以及对可用治疗方法整体缺乏认识等挑战也可能阻碍市场的进步。不利的报销条件也可能是一个主要障碍，影响专注于针对性研究和开发的製药公司的商机。儘管面临这些挑战，美国市场情势预计在下一个预测期内将保持稳定的复合年增长率。这反映了在不断发展的医疗保健环境中对治疗的持续需求，该环境越来越优先考虑与睡眠相关的疾病。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Jazz Pharmaceuticals plc
Teva Pharmaceutical Industries Ltd.
Bioprojet Pharma SARL
Novartis International AG
Takeda Pharmaceutical Company
Avadel Pharmaceuticals
Mylan NV（now part of Viatris）
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals
Otsuka Pharmaceutical
Biogen
Theravance Biopharma
Ligand Pharmaceuticals
Flamel Technologies（now Avadel Pharmaceuticals）
Biocodex
Sun Pharmaceutical Industries
Cipla Limited
Dr. Reddy's Laboratories
Pfizer Inc.

简介目录

Product Code: SQMIG35I2087

Global Narcolepsy Drugs Market size was valued at around USD 3.4 billion in 2022 and is expected to rise from USD 3.7 billion in 2023 to reach a value of USD 7 billion by 2031, at a CAGR of 9.5% over the forecast period (2024-2031).

The narcolepsy therapeutics market is poised for substantial growth driven by several key factors, primarily the aging population's increased susceptibility to chronic and acute ailments necessitating medical care. The rise in narcoleptic disorders, exacerbated by evolving lifestyles and heightened stress levels, is expected to further fuel market expansion in the coming years. Enhanced research initiatives, increased healthcare spending, and improved medical infrastructure underscore this growth potential. Additionally, factors such as circadian adjustment, increased sleep, and telework practices suggest that symptoms associated with central hypersomnia can be effectively managed, encouraging a broader acceptance of narcolepsy treatments. However, challenges exist, notably the high costs associated with treatments and diagnostics, coupled with an overarching lack of awareness regarding available therapies, which are likely to hinder market progress. The unfavorable reimbursement landscape also poses significant obstacles, potentially impacting revenue opportunities for pharmaceutical companies focused on targeted research and development. Despite these challenges, the US narcolepsy drugs market is expected to experience a steady compound annual growth rate (CAGR) over the next forecast period, reflecting a resilient demand for treatments amid an evolving healthcare landscape that increasingly prioritizes sleep-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Narcolepsy Drugs Market

Growing awareness surrounding narcolepsy treatment plays a crucial role in driving the Global Narcolepsy Drugs market from 2023 to 2030. As more patients and healthcare providers recognize the impact of the condition on quality of life, the demand for effective treatments is surging. Notably, the preference for modafinil, which is known for its favorable safety profile compared to traditional stimulants, is further contributing to this trend. This increased focus on appropriate therapeutic options not only enhances patient outcomes but also fosters market growth, as effective therapies become more widely adopted, driving sales and innovation within the narcolepsy drug sector.

Restraints in the Global Narcolepsy Drugs Market

A significant market restraint for the global narcolepsy drugs market is the frequent misdiagnosis of narcolepsy symptoms, which are often confused with various mental and neurological disorders. This lack of awareness leads to inappropriate prescriptions of antiepileptics and psychiatric medications, particularly in children and adolescents, potentially causing adverse health effects. The resulting hesitation from healthcare providers to accurately diagnose and treat narcolepsy can hinder market growth, as patients may not receive the necessary therapy for their condition. Additionally, this confusion can create mistrust among patients towards seeking effective treatments, further limiting market opportunities for narcolepsy drug manufacturers.

Market Trends of the Global Narcolepsy Drugs Market

The global narcolepsy drugs market is poised for significant growth, fueled by the rising prevalence of narcolepsy and associated sleep disorders across diverse demographics. Increasing incidences of obesity-related narcolepsy variants further bolster market expansion, highlighting the pressing need for effective therapeutic solutions. Government initiatives aimed at enhancing awareness and understanding of narcolepsy are anticipated to drive demand for treatment options. Moreover, hospitals are emerging as the primary end-use sector, capturing the largest share of the market as more patients seek specialized care. Overall, this confluence of factors positions the narcolepsy drugs market for robust growth in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis
Clinical Trials

Narcolepsy Drugs Market, By Disease Type

Market Overview
Daytime Extreme Sleepiness
Cataplexia
Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

Market Overview
Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Other Therapeutic Type

Narcolepsy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet Pharma SARL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (now part of Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies (now Avadel Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments